RS51859B - Method for predicting the response to a treatment with a her dimerization inhibitor - Google Patents

Method for predicting the response to a treatment with a her dimerization inhibitor

Info

Publication number
RS51859B
RS51859B RS20110132A RSP20110132A RS51859B RS 51859 B RS51859 B RS 51859B RS 20110132 A RS20110132 A RS 20110132A RS P20110132 A RSP20110132 A RS P20110132A RS 51859 B RS51859 B RS 51859B
Authority
RS
Serbia
Prior art keywords
marker
growth factor
gene
alpha
transforming growth
Prior art date
Application number
RS20110132A
Other languages
Serbian (sr)
Inventor
Joachim Moecks
Andreas Strauss
Gerhard Zugmaier
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51859(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of RS51859B publication Critical patent/RS51859B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)

Abstract

METODA ZA PREDVIĐANJE ODGOVORA NA TRETMAN INHIBITORIMA DIMERIZACIJE HER, kod pacijenata koja obuhvata sledeće stupnjeve:a) određivanje, u uzorku biološkog materijala pacijenta, gde je taj uzorak krvni serum, nivoa ekspresije- marker proteina kodiranog marker genom za transformišući faktor rasta alfa ili- kombinacije marker proteina koju kodiraju marker geni, gde se kombinacija marker proteina koju kodiraju marker geni sastoji od marker proteina koje kodiraju- marker gen za transformišući faktor rasta alfa i za HER2,- marker gen za transformišući faktor rasta alfa i marker epidermalnog faktora rasta,- marker gen za amfiregulin i marker transformišućeg faktor rasta alfa- marker gen za transformišući faktor rasta alfa, epidermalni faktor rasta i marker HER2,- marker gen za amfiregulin, za epidermalni faktor rasta i marker transformišućeg faktora rasta alfa,- marker gen za amfiregulin, gen za transformišući faktor rasta alfa i marker HER2,- marker gen za epidermalni faktor rasta, transformišući faktor rasta alfa i marker HER2,- marker gen za amfiregulin, epidermalni faktor rasta, za transformišući faktor rasta alfa i marker HER2,b) za predviđanje odgovora na tretiranje pacijenta inhibitorom dimerizacije HER procenjivanjem rezultata stupnjeva a).Prijava sadrži još 14 patentnih zahteva.METHOD FOR PREDICTING RESPONSE TO TREATMENT WITH HER DIMERIZATION INHIBITORS, in patients comprising the following steps: a) determination, in a sample of the patient's biological material, where the sample is blood serum, marker proteins encoded by marker genes, where the combination of marker proteins encoded by marker genes consists of marker proteins encoded - marker gene for transforming growth factor alpha and for HER2, - marker gene for transforming growth factor alpha and marker of epidermal growth factor, - marker gene for amphiregulin and transforming growth factor marker alpha- marker gene for transforming growth factor alpha, epidermal growth factor and marker HER2, - marker gene for amphiregulin, for epidermal growth factor and marker of transforming growth factor alpha, - marker gene for amphiregulin, gene for transforming growth factor alpha and marker HER2, - marker gene for epidermal growth factor, transform alpha growth marker and HER2 marker, - marker gene for amphiregulin, epidermal growth factor, for transforming growth factor alpha and HER2 marker, b) for predicting response to treatment of a patient with HER dimerization inhibitor by evaluating the results of steps a). The application contains 14 more patent claims .

RS20110132A 2005-08-12 2006-05-24 Method for predicting the response to a treatment with a her dimerization inhibitor RS51859B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05017663 2005-08-12

Publications (1)

Publication Number Publication Date
RS51859B true RS51859B (en) 2012-02-29

Family

ID=35511140

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20110132A RS51859B (en) 2005-08-12 2006-05-24 Method for predicting the response to a treatment with a her dimerization inhibitor

Country Status (32)

Country Link
US (2) US7700299B2 (en)
EP (2) EP1915460B1 (en)
JP (1) JP2009504142A (en)
KR (2) KR20110074921A (en)
CN (2) CN101705287A (en)
AR (1) AR057323A1 (en)
AT (2) ATE539171T1 (en)
AU (2) AU2006281746B2 (en)
BR (1) BRPI0615001A2 (en)
CA (1) CA2616913A1 (en)
CL (1) CL2010000720A1 (en)
CR (1) CR9686A (en)
CY (1) CY1111612T1 (en)
DE (1) DE602006019265D1 (en)
DK (1) DK1915460T3 (en)
EC (1) ECSP088171A (en)
ES (1) ES2356066T3 (en)
HR (1) HRP20110171T1 (en)
IL (1) IL188923A0 (en)
MA (1) MA31549B1 (en)
MX (1) MX2008001926A (en)
NO (1) NO20080371L (en)
NZ (1) NZ565270A (en)
PL (1) PL1915460T3 (en)
PT (1) PT1915460E (en)
RS (1) RS51859B (en)
RU (2) RU2408735C2 (en)
SI (1) SI1915460T1 (en)
TW (1) TW200741010A (en)
UA (1) UA93989C2 (en)
WO (1) WO2007019899A2 (en)
ZA (1) ZA201102688B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JP2003534292A (en) * 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド ERBB antagonist gene detection assays to increase the likelihood of effective response to cancer treatment
SV2006002143A (en) * 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
US7560111B2 (en) * 2004-07-22 2009-07-14 Genentech, Inc. HER2 antibody composition
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
CN101115849A (en) * 2004-12-07 2008-01-30 健泰科生物技术公司 Selecting patients for therapy with a her inhibitor
US7449184B2 (en) * 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
PT1850874E (en) * 2005-02-23 2013-12-02 Genentech Inc Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (en) * 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
US8129114B2 (en) * 2005-08-24 2012-03-06 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
PE20090681A1 (en) 2007-03-02 2009-06-10 Genentech Inc PREDICTION OF RESPONSE TO A HER INHIBITOR
JP5433189B2 (en) * 2007-09-28 2014-03-05 承一 尾崎 Method of providing material for predicting the effect of treatment on subjects with MPO-ANCA-related vasculitis
US10416162B2 (en) * 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
NZ586544A (en) * 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
KR20160066557A (en) * 2008-03-14 2016-06-10 제넨테크, 인크. Genetic variations associated with drug resistance
WO2009140409A1 (en) 2008-05-14 2009-11-19 Genomic Health Inc. Predictors of patient response to treatment with egf receptor inhibitors
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
WO2010083470A1 (en) 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-3
WO2010083463A1 (en) * 2009-01-15 2010-07-22 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of her-2 expression
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
CN103109185A (en) * 2010-04-18 2013-05-15 耶达研究及发展有限公司 Molecules and methods of using same for treating erbb/erbb ligands associated diseases
BR112013017411B1 (en) * 2011-01-07 2022-03-22 Anji Pharma (Us) Llc Use of a composition comprising metformin or a salt thereof
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
WO2013052745A1 (en) * 2011-10-06 2013-04-11 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
HUE044352T2 (en) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer
AU2012363873B2 (en) 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
EA033067B1 (en) 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Method for treating metabolic disorders in a patient having a contraindication for a biguanide compound
NZ712012A (en) 2013-04-16 2020-04-24 Genentech Inc Pertuzumab variants and evaluation thereof
US20160175401A1 (en) * 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
EP2876442A1 (en) 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
KR20160141857A (en) 2014-04-25 2016-12-09 제넨테크, 인크. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
WO2016011432A2 (en) 2014-07-17 2016-01-21 Czerniecki Brian J Identification of immunogenic mhc class ii peptides for immune-based therapy
CN107614015A (en) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 Treat HER2 positives Locally Advanced or the previously method of untreated metastatic breast cancer
EP3325005A4 (en) * 2015-07-17 2019-03-27 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN105403704A (en) * 2015-12-31 2016-03-16 苏州市博纳泰科生物技术有限公司 Fluorescence immunoassay detection method and kit for HER-2
CA3040913A1 (en) 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
KR102313262B1 (en) 2016-12-28 2021-10-14 제넨테크, 인크. Treatment of advanced HER2-expressing cancer
TWI729259B (en) 2017-01-17 2021-06-01 美商建南德克公司 Subcutaneous her2 antibody formulations
HUE064898T2 (en) 2017-03-02 2024-04-28 Genentech Inc Adjuvant treatment of her2-positive breast cancer
TW201902509A (en) 2017-04-24 2019-01-16 美商建南德克公司 ERBB2/HER2 mutation
BR112020023968A2 (en) * 2018-05-25 2021-02-23 Bioneer Corporation amphiregulin-specific double-stranded oligonucleotide, structure, nanoparticle, pharmaceutical composition and lyophilized formulation comprising the same
WO2024036234A1 (en) * 2022-08-09 2024-02-15 Heligenics Inc. Method for evaluating clinical relevance of genetic variance

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
BR9712410A (en) 1996-10-18 1999-10-19 Genentech Inc Isolated antibody, composition, nucleic acid, vector, host cell, method for making an anti-erbb2 antibody, method for determining the presence of erbb2, kit, method for inducing cell death and manufactured article
BR122014028365B8 (en) 1999-06-25 2021-07-06 Genentech Inc manufactured article comprising a first container comprising a composition of humab4d5-8 contained therein and a second container comprising a composition of rhumab 2c4 contained therein
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP3115470B1 (en) 2002-03-13 2018-07-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
MXPA05000403A (en) * 2002-07-15 2005-07-22 Genentech Inc METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES.
CA2509543C (en) * 2002-12-11 2017-06-06 Ventana Medical Systems, Inc. Method for predicting the response to her2-directed therapy
EP1590487A2 (en) 2003-02-06 2005-11-02 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
BRPI0408961A (en) 2003-04-01 2006-10-31 Monogram Biosciences Inc method for determining a patient's disease condition, method for selecting a patient for cancer treatment with one or more erbb dimeric drugs, and method for determining a patient's cancerous condition
EP2348110B1 (en) 2003-05-30 2013-03-27 OncoTherapy Science, Inc. Process for screening a drug response in cancer patients
WO2005011607A2 (en) 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
US20080113344A1 (en) 2003-10-28 2008-05-15 Ralph Wirtz Methods and Compositions for the Response Prediction of Malignant Neoplasia to Treatment
TWM256978U (en) * 2004-04-02 2005-02-11 Nventec Appliances Corp Electronic device
CN101115849A (en) * 2004-12-07 2008-01-30 健泰科生物技术公司 Selecting patients for therapy with a her inhibitor

Also Published As

Publication number Publication date
CN101705287A (en) 2010-05-12
KR20110074921A (en) 2011-07-04
ZA201102688B (en) 2012-01-25
NO20080371L (en) 2008-05-09
ECSP088171A (en) 2008-03-26
EP1915460B1 (en) 2010-12-29
MX2008001926A (en) 2008-03-24
WO2007019899A8 (en) 2010-08-05
KR20080034922A (en) 2008-04-22
SI1915460T1 (en) 2011-04-29
US20070037228A1 (en) 2007-02-15
IL188923A0 (en) 2008-08-07
AU2006281746B2 (en) 2011-06-23
CL2010000720A1 (en) 2010-12-03
TW200741010A (en) 2007-11-01
RU2010115252A (en) 2011-10-27
RU2408735C2 (en) 2011-01-10
JP2009504142A (en) 2009-02-05
AU2011202339A1 (en) 2011-06-09
BRPI0615001A2 (en) 2011-04-26
ES2356066T3 (en) 2011-04-04
ATE539171T1 (en) 2012-01-15
UA93989C2 (en) 2011-03-25
CY1111612T1 (en) 2015-10-07
RU2008108907A (en) 2009-09-20
CN101405405A (en) 2009-04-08
WO2007019899A3 (en) 2007-04-05
DK1915460T3 (en) 2011-01-31
DE602006019265D1 (en) 2011-02-10
WO2007019899A2 (en) 2007-02-22
ATE493514T1 (en) 2011-01-15
EP2196547B1 (en) 2011-12-28
EP1915460A2 (en) 2008-04-30
MA31549B1 (en) 2010-08-02
US7700299B2 (en) 2010-04-20
US20100112603A1 (en) 2010-05-06
CA2616913A1 (en) 2007-02-22
AR057323A1 (en) 2007-11-28
PL1915460T3 (en) 2011-05-31
PT1915460E (en) 2011-03-17
CR9686A (en) 2008-02-20
HRP20110171T1 (en) 2011-04-30
EP2196547A1 (en) 2010-06-16
NZ565270A (en) 2011-05-27
AU2006281746A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
RS51859B (en) Method for predicting the response to a treatment with a her dimerization inhibitor
NO20074389L (en) Determination of responders to chemotherapy
Steyer et al. First histological and skeletochronological data on temnospondyl growth: palaeoecological and palaeoclimatological implications
NZ593226A (en) Gene expression markers (efnb2) for colorectal cancer prognosis
MX2007006529A (en) Selecting patients for therapy with a her inhibitor.
UA116618C2 (en) CONSTITUTION-BASED CYSTEINE ANTIBODY AGAINST CD79b
EA200701426A1 (en) THE COMPOSITION OF THE TICKS, ITS APPLICATION, THE METHOD OF BREEDING THE PREDATORY MILE - PHYTOSEIDA AMBLYSEIUS SWIRSKII, THE SYSTEM FOR THE DEVELOPMENT OF THE SPECIFIED PREFERABLE TICKS AND THE METHOD OF BIOLOGICAL CONTROL OF THE PREVENTIVE TARGET
DE602005006990D1 (en) RECOVERY DESTROYED TISSUE WITH THE HELP OF MULTIPOTENTIAL CELLS
AU2002952548A0 (en) Diagnostic assay
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
ATE556717T1 (en) NEUTRALIZATION OF MONOCLONAL ANTIBODIES AGAINST CORONAVIRUS ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME
ATE459883T1 (en) NEW PROLIFERATION MARKERS IN CLINICAL PRACTICE AND THEIR USE FOR CANCER PROGNOSIS OR DIAGNOSIS
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
AR056125A1 (en) PROCEDURE FOR THE DIAGNOSIS OF THROMBOEMBOLIES AND ISCHEMICAL CARDIOPATIAS
ATE547534T1 (en) METHOD FOR THE NON-INVASIVE INVESTIGATION OF NON-ALCOHOLIC STEATOHEPATITIS USING QUANTIFICATION OF CYTOCHROME-C
DE602004030036D1 (en) Multiplex analysis of nucleic acids for the determination of human papillomavirus genotypes
DE602004027086D1 (en) CLASSIFICATION OF COLONY CANCER
DK1795897T3 (en) Predictive testing of therapeutic response for mammary cancer
DE602006020601D1 (en) PROCESS FOR USE OF IL-21
DE502004012140D1 (en) A method for the in-vitro diagnosis of a glioma or astrocytoma and pharmaceutical mixture for the treatment of glioma, astrocytoma or a recurrence thereof
ATE423321T1 (en) METHOD FOR DETECTING PRPSC USING GROUP II AMINOGLYCOSIDE ANTIBIOTICS
WO2008014296A3 (en) Composition and method for treatment of tumors
WO2005096693A3 (en) Cancer prognosis and/or diagnosis method
AR056831A1 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES